Sanofi Pauses Heart Disease Drug Patent Dispute With Amgen
Sanofi and Regeneron persuaded the Unified Patent Court on Wednesday to pause their clash with Amgen over a patent for a heart disease drug while awaiting the outcome of an appeal...To view the full article, register now.
Already a subscriber? Click here to view full article